ATE528410T1 - Verfahren und zusammensetzungen zur diagnose von altersbedingter maculadegeneration - Google Patents

Verfahren und zusammensetzungen zur diagnose von altersbedingter maculadegeneration

Info

Publication number
ATE528410T1
ATE528410T1 AT05851755T AT05851755T ATE528410T1 AT E528410 T1 ATE528410 T1 AT E528410T1 AT 05851755 T AT05851755 T AT 05851755T AT 05851755 T AT05851755 T AT 05851755T AT E528410 T1 ATE528410 T1 AT E528410T1
Authority
AT
Austria
Prior art keywords
macular degeneration
related macular
compositions
methods
amd
Prior art date
Application number
AT05851755T
Other languages
German (de)
English (en)
Inventor
Josephine Hoh
Robert Klein
Original Assignee
Univ Yale
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale, Univ Rockefeller filed Critical Univ Yale
Application granted granted Critical
Publication of ATE528410T1 publication Critical patent/ATE528410T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT05851755T 2004-11-18 2005-11-18 Verfahren und zusammensetzungen zur diagnose von altersbedingter maculadegeneration ATE528410T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US62936304P 2004-11-18 2004-11-18
US64947905P 2005-02-02 2005-02-02
US67234605P 2005-04-18 2005-04-18
PCT/US2005/041664 WO2006062716A2 (en) 2004-11-18 2005-11-18 Methods and compositions for treating ocular disorders

Publications (1)

Publication Number Publication Date
ATE528410T1 true ATE528410T1 (de) 2011-10-15

Family

ID=36578383

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05851755T ATE528410T1 (de) 2004-11-18 2005-11-18 Verfahren und zusammensetzungen zur diagnose von altersbedingter maculadegeneration

Country Status (14)

Country Link
US (3) US20090017029A1 (https=)
EP (1) EP1836312B1 (https=)
JP (2) JP2008520242A (https=)
KR (1) KR101290621B1 (https=)
CN (2) CN102618644A (https=)
AT (1) ATE528410T1 (https=)
AU (1) AU2005314461B2 (https=)
BR (1) BRPI0518289A2 (https=)
CA (1) CA2588270A1 (https=)
CY (1) CY1112579T1 (https=)
DK (1) DK1836312T3 (https=)
ES (1) ES2375490T3 (https=)
IL (1) IL183284A (https=)
WO (1) WO2006062716A2 (https=)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004047514A2 (en) 2002-11-25 2004-06-10 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
BRPI0506629A (pt) 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
US7745389B2 (en) * 2005-02-14 2010-06-29 University Of Iowa Research Foundation Methods for treatment of age-related macular degeneration
WO2006128006A1 (en) 2005-05-26 2006-11-30 The Regents Of The University Of Colorado Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
SG10201804008UA (en) * 2005-11-04 2018-06-28 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
WO2007120975A2 (en) * 2006-02-13 2007-10-25 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Variants in complement regulatory genes predict age-related macular degeneration
CA2638916A1 (en) * 2006-02-13 2007-08-23 University Of Iowa Research Foundation Variants in complement regulatory genes predict age-related macular degeneration
US8012683B2 (en) 2006-02-13 2011-09-06 University Of Iowa Research Foundation Variants in complement regulatory genes predict age-related macular degeneration
US7759304B2 (en) 2006-06-21 2010-07-20 Regents Of The University Of Colorado Targeting complement factor H for treatment of diseases
EP2479284B1 (en) * 2006-07-13 2017-09-20 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
AU2016204271B2 (en) * 2006-07-13 2018-04-19 University Of Iowa Research Foundation Methods and reagents for the treatment and diagnosis of vascular disorders and age-related macular degeneration
ES2391788T3 (es) * 2006-07-26 2012-11-29 Yale University, Inc. Diagnóstico y tratamiento de degeneración macular relacionada con la edad
CN101173314B (zh) * 2006-10-18 2010-12-01 四川省医学科学院（四川省人民医院） 检测老年黄斑变性疾病的试剂盒
TW201716437A (zh) 2006-11-02 2017-05-16 建南德克公司 人類化之抗-因子ｄ抗體及其用途
GB0701213D0 (en) * 2007-01-23 2007-02-28 Univ Cardiff Factor H polymorphisms in the diagnosis and therapy of inflammatory diseases such as age-related macular degeneration
WO2008103299A2 (en) 2007-02-16 2008-08-28 Massachusetts Eye & Ear Infirmary Methods and compositions for prognosing, detecting, and treating age-related macular degeneration
CN101668773B (zh) 2007-03-14 2016-08-31 亚力史制药公司 人工程化抗b因子抗体
JP5226256B2 (ja) * 2007-07-26 2013-07-03 ニプロ株式会社 加齢黄斑変性症の発症リスクの予測方法
WO2009059321A2 (en) * 2007-11-01 2009-05-07 University Of Iowa Research Foundation Rca locus analysis to assess susceptibility to amd and mpgnii
US8114592B2 (en) 2008-03-18 2012-02-14 Cambridge Enterprise Limited Genetic markers associated with age-related macular degeneration, methods of detection and uses thereof
US20110190221A1 (en) * 2008-03-28 2011-08-04 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
DK2540843T3 (da) * 2008-11-05 2014-09-01 Genentech Inc Genetiske polymorfismer ved aldersbetinget makulær degeneration
US20120115925A1 (en) * 2008-12-23 2012-05-10 Massachusetts Eye And Ear Infirmary Allelic Variants Associated with Advanced Age-Related Macular Degeneration
KR100937720B1 (ko) * 2009-04-20 2010-01-20 전남대학교산학협력단 ＣＦＨ 또는 ＡｐｏＨ를 급성골수성백혈병 관해 진단용 생화학적 마커로 사용하는 방법
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
CA2795311A1 (en) 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
US20130011857A1 (en) 2010-02-12 2013-01-10 Cemm Forschungszentrum Fur Molekulare Medizin Gmbh Complement factor h for oxidative stress disease conditions
BR112012029067A2 (pt) 2010-05-14 2019-09-24 Univ Colorado Regents grupos-alvo de receptor do complemento 2 (cr2) melhorados.
WO2011153234A2 (en) * 2010-06-01 2011-12-08 University Of Kentucky Research Foundation Methods of inhibiting alu rna and therapeutic uses thereof
WO2011163394A2 (en) 2010-06-22 2011-12-29 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
SG186397A1 (en) 2010-06-22 2013-01-30 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3
JP2014502953A (ja) 2010-08-16 2014-02-06 ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 細胞透過性治療薬の鼻腔内送達
FR2983212A1 (fr) 2011-11-28 2013-05-31 Lfb Biotechnologies Aptameres anti-fh, procede pour leur obtention et utilisations
FR2988298A1 (fr) * 2012-03-23 2013-09-27 Lfb Biotechnologies Facteur h pour son utilisation comme molecule antioxydante
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
CN102707068B (zh) * 2012-05-31 2015-03-18 北京大学 补体h因子用作甲基苯丙胺成瘾患者的基因表达产物中的应用
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
MX366404B (es) 2012-11-15 2019-07-08 Apellis Pharmaceuticals Inc Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y composiciones y metodos relacionados.
AU2014236778B2 (en) 2013-03-14 2019-01-03 Baxalta GmbH Factor H for transplantation
JP5721150B2 (ja) * 2013-03-14 2015-05-20 学校法人 埼玉医科大学 加齢黄斑変性症の発症リスクの予測方法
WO2014151923A1 (en) 2013-03-14 2014-09-25 Baxter International Inc. Factor h for treatment of rheumatoid arthritis
AU2013202965B2 (en) 2013-03-15 2016-07-21 Takeda Pharmaceutical Company Limited Improved method for producing factor h from a plasma precipitation fraction
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
SG11201601044XA (en) 2013-08-12 2016-03-30 Genentech Inc Compositions and method for treating complement-associated conditions
US20150093331A1 (en) * 2013-10-01 2015-04-02 OncoLock Co., Ltd. Biomarkers for breast cancer
KR102131973B1 (ko) * 2013-12-30 2020-07-08 주식회사 케이티 개인 건강관리 방법 및 시스템
ES2824262T3 (es) * 2014-02-26 2021-05-11 Allergan Inc Anticuerpos contra componente C5 del complemento
US10155983B2 (en) 2014-03-31 2018-12-18 Machaon Diagnostics, Inc. Method of diagnosis of complement-mediated thrombotic microangiopathies
AU2015253042A1 (en) 2014-05-01 2016-10-20 Genentech, Inc. Anti-factor D antibody variants and uses thereof
KR102314785B1 (ko) * 2015-04-21 2021-10-19 인제대학교 산학협력단 신규한 황반변성 진단용 마커 및 황반변성 진단방법
US11903994B2 (en) 2015-10-07 2024-02-20 Apellis Pharmaceuticals, Inc. Dosing regimens
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
CN106248968A (zh) * 2015-11-01 2016-12-21 李倩 一种用于检测眼科疾病的试剂盒及其检测方法
WO2017096031A1 (en) * 2015-12-03 2017-06-08 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf
KR102011182B1 (ko) * 2016-10-07 2019-08-16 단국대학교 천안캠퍼스 산학협력단 익상편 과발현 유전자 및 이의 용도
IL269844B2 (en) 2017-04-07 2025-01-01 Apellis Pharmaceuticals Inc Dosage regimens and related compositions and methods
WO2019118938A1 (en) 2017-12-15 2019-06-20 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
US20210338838A1 (en) * 2018-07-20 2021-11-04 University Of Utah Research Foundation Gene therapy for macular degeneration
KR102302571B1 (ko) * 2019-03-07 2021-09-16 (주)레티마크 나이관련 황반변성 진단용 복합 마커 및 이의 용도
CA3167756A1 (en) * 2020-02-04 2021-08-12 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with son of sevenless 2 (sos2) inhibitors
KR102333953B1 (ko) * 2020-07-10 2021-12-02 인제대학교 산학협력단 신규한 황반변성 진단용 유전자 마커
CN113293206A (zh) * 2021-07-23 2021-08-24 西安医臻生物医药科技有限公司 一种快速鉴别老年黄斑病变风险的方法及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1284931C (en) * 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
CA2336703A1 (en) * 1998-07-10 2000-01-20 The University Of Sydney Prophylactic treatments of neovascularisation in macular degeneration
AU2001245489A1 (en) * 2000-03-07 2001-09-17 Whitehead Institute For Biomedical Research Human single nucleotide polymorphisms
JP4764590B2 (ja) * 2000-04-29 2011-09-07 ユニバーシティー オブ アイオワ リサーチ ファウンデーション 黄班変性関連疾患の診断および治療
CN1466953A (zh) * 2003-01-15 2004-01-14 哈佛东方生物医药（云南）有限公司 预防治疗老年黄斑变性的复合制剂
US7745389B2 (en) * 2005-02-14 2010-06-29 University Of Iowa Research Foundation Methods for treatment of age-related macular degeneration

Also Published As

Publication number Publication date
WO2006062716A2 (en) 2006-06-15
KR101290621B1 (ko) 2013-07-29
CN102618644A (zh) 2012-08-01
CN101142321B (zh) 2012-06-06
AU2005314461B2 (en) 2012-02-02
JP2008520242A (ja) 2008-06-19
BRPI0518289A2 (pt) 2008-11-11
AU2005314461A1 (en) 2006-06-15
EP1836312B1 (en) 2011-10-12
US20120135000A1 (en) 2012-05-31
US20140018306A1 (en) 2014-01-16
KR20070105969A (ko) 2007-10-31
US20090017029A1 (en) 2009-01-15
WO2006062716A3 (en) 2006-10-05
IL183284A (en) 2014-09-30
HK1113690A1 (en) 2008-10-10
ES2375490T3 (es) 2012-03-01
JP2012080900A (ja) 2012-04-26
DK1836312T3 (da) 2012-03-12
CN101142321A (zh) 2008-03-12
EP1836312A2 (en) 2007-09-26
IL183284A0 (en) 2007-09-20
CY1112579T1 (el) 2016-02-10
CA2588270A1 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
ATE528410T1 (de) Verfahren und zusammensetzungen zur diagnose von altersbedingter maculadegeneration
ATE440536T1 (de) Verfahren zur diagnose, behandlung und prävention von knochenverlust
ATE488251T1 (de) Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen
SG141418A1 (en) Method for the detection of gene transcripts in blood and uses thereof
ATE533061T1 (de) Verfahren zur diagnose bakterieller infektionen
ATE526041T1 (de) Verfahren zur hemmung okularer vorgänge
ATE478062T1 (de) Zusammensetzungen und verfahren zur in vivo abbildung von loeslichen beta-amyloid
PL2341344T3 (pl) Sposób diagnozowania wielotorbielowatości nerek
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
WO2005058961A3 (en) Antibodies specific for human galanin, and uses thereof
DE602006018035D1 (de) Verfahren und kit zur quantitativen bestimmung von small, dense ldl cholesterol
EP2189541A3 (en) Methods and reagents for treatment and diagnosis of age-related macular degeneration
ATE422671T1 (de) Verfahren zur diagnose von morbus alzheimer
DE602004029061D1 (de) Zusammensetzungen, reagenzien, kits und verfahren für die diagnose und behandlung von fettleibigkeit und/oder diabetes
WO2005098433A3 (en) Diagnostic assays for alzheimer’s disease
DE602008004556D1 (de) Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin
DE602004026683D1 (de) Verfahren zur diagnose und überwachung von neurologischen erkrankungen durch nachweis eines encephalotoxins
DE602007004570D1 (de) Verwendung von Nogo-C bei der Beurteilung von Herzversagen
EP1363528A4 (en) METHODS OF DIAGNOSING AND TREATING CARDIOPATHIES
EP3935190A4 (en) Reagents, methods and kits for identifying pregnant human beings at risk for placental bed disorder(s)
ATE390435T1 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von diabetes, insulinresistenz und dyslipidämie
ATE501276T1 (de) Verfahren zur gliomdiagnose mit unterscheidung zwischen progressiven und de-novo-formen
DE602004024992D1 (de) Verwendung von pyrazolopyridinen zur behandlung von kognitiven defiziten
WO2006032021A3 (en) Identification of gene associated with reading disability and uses therefor
DE602005016582D1 (de) Ein die mam-domäne enthaltendes protein

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1836312

Country of ref document: EP